Acute myeloid leukemia (AML) is the most common form of leukemia in adults and has historically been associated with poor five-year overall survival rates. In recent years, the AML treatment…
Since 2015, eleven new brands have launched in the Parkinson’s disease (PD) therapy market (e.g., Inbrija [Acorda], Kynmobi [Sunovion], Ongentys [Neurocrine]), and several more are on the horizon…
Prostate Cancer
The wet age-related macular degeneration (AMD) therapy market has long been dominated by three VEGF inhibitors: Roche / Genentech / Chugai’s Avastin, Roche / Genentech / Novartis’s Lucentis,…
The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and the long treatment durations. The availability of premium-priced branded agents prescribed…
Hormonal agents are the mainstay treatment for prostate cancer and are routinely used in all lines of therapy. Next-generation hormonal treatment has expanded beyond metastatic castrate-resistant…
The market for NASH, a severe form of nonalcoholic fatty liver disease (NAFLD), offers substantial commercial opportunity to drug developers owing to the lack of approved agents and the disease’s…
Although the tumor necrosis factor-alpha (TNF-α) inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) patients refractory to conventional DMARD treatment (the first…
Although the tumor necrosis factor-alpha (TNF-α) inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) patients refractory to conventional DMARD treatment (the first…
Retinal Vein Occlusion
Methicillin-Resistant Staphylococcus Aureus Infections
Chronic Fatigue Syndrome
Pre-exposure prophylaxis (PrEP) is a key prevention strategy for ending the human immunodeficiency virus (HIV) epidemic. The FDA’s approval of Gilead’s Truvada in 2012 and Descovy in 2019…
The schizophrenia therapy market is very crowded, with multiple oral long-acting injectable (LAI) antipsychotic agents. Indeed, to gain a foothold in the market, differentiation from already…
Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, including several targeted and biomarker-driven therapies…